The theme of Sibos 2018 is ‘Enabling the digital economy’ - split into 4 sub-themes.
Which will undoubtedly make for an interesting conference and we look forward to having some very in-depth and exciting discussions surrounding these thematics; especially concerning the role of AI in the financial sector, and how it can support the fast changing geopolitical and regulatory priorities around the world. Let's talk >>
On September 21, 2015, at 10:56 a.m., then-candidate for President Hillary Clinton tweeted about ‘price gouging’ in the specialty drug market. By 4 p.m. that day, the entire Biotech sector had tanked. The iShares Nasdaq Biotechnology ETF (IBB) – which had skyrocketed nearly 300% over the previous five years – sunk 5% in the five hours from Clinton tweet to closing bell. The nine biggest losers on the Nasdaq 100 that day were all Biotech stocks, and the Nasdaq plunged into the red on a positive day for most other sectors...
In December 2016, The Economist studied equity analyst ratings for all stocks in the S&P 500 index. According to the study, 49% of the ratings were "buy/outperform,” and 45% were "hold/neutral." Only 6% of all ratings for the S&P 500 in 2016 were "sell/underperform.” Yet during that same year, nearly half of all S&P 500 stocks underperformed the market index, and a full 30% were in the red.How did the analysts get it so wrong? Are they ill-equipped to properly research and analyze a given company, or is there another hidden factor at play?